October 14, 2019 / 3:45 PM / 2 months ago

BRIEF-Lonza Says Ibex Solutions To Support Genmab Clinical Portfolio

Oct 14 (Reuters) - Lonza Group Ag:

* SAYS IBEX SOLUTIONS TO SUPPORT GENMAB’S GROWING CLINICAL PORTFOLIO

* SAYS IBEX DEVELOP WILL ENABLE GENMAB TO SUPPORT EXPANDING PIPELINE DEMAND FOR PRODUCT ACROSS ALL CLINICAL PHASES AND TOWARDS POTENTIAL LAUNCH

* SAYS FLEXIBLE ASSET MANAGEMENT DESIGNED TO PROVIDE SECURE CAPACITY FOR GENMAB ACROSS PORTFOLIO OF CANDIDATES

* SAYS NEW AGREEMENT WILL COVER DEVELOPMENT, CLINICAL MANUFACTURING OF DRUG SUBSTANCE AND DRUG PRODUCT FOR CERTAIN PROGRAMS IN GENMAB’S PRE-CLINICAL AND CLINICAL PIPELINE. INCLUDING MORE COMPLEX MOLECULAR FORMATS DEVELOPED USING GENMAB’S DUOBODY TECHNOLOGY Further company coverage: (Reporting by John Miller)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below